#AS­CO21: Eli Lil­ly-part­nered Merus re­veals new da­ta for NRG1 fu­sion can­cers in­clud­ing pan­cre­at­ic and NSCLC

One of Eli Lil­ly’s newest R&D part­ners re­vealed some new da­ta at #AS­CO21 for an in-house pro­gram, and it’s one that could cov­er a broad range of sol­id tu­mors with rare ge­net­ic mu­ta­tions.

The Dutch biotech Merus NV re­port­ed that their ex­per­i­men­tal drug zeno­cu­tuzum­ab, re­ferred to as “zeno,” in­duced par­tial re­spons­es in 13 of 45 pa­tients with NRG1 fu­sion-pos­i­tive can­cers as of April 13 cut­off date, good for an over­all re­sponse rate of 29%. Merus is eval­u­at­ing the can­di­date in a sin­gle-arm Phase I/II study with 61 en­rolled pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER